Search research articles
Contact Us
Filters
Showing results (141-150 of 181) with videos related to
Page
of 19
Sort By:
British Journal of Cancer
|
May 26, 2023
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
Anthony B El-Khoueiry, James Clarke, Tobias Neff, et al.
Molecular Cancer Therapeutics
|
January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
Filip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.
International Journal of Cancer
|
January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
Ignacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Filip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Cancer Biology & Therapy
|
July 20, 2011
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
Georg Feldmann, Anjali Mishra, Savita Bisht, et al.
Oncotarget
|
December 19, 2012
PIK3CA mutations in advanced cancers: characteristics and outcomes
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
JCO Precision Oncology
|
May 9, 2024
Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets
Erik B Faber, Harris B Krause, Khalid Amin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2011
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer
Ignacio Garrido-Laguna, Maria Uson, N V Rajeshkumar, et al.
The Oncologist
|
August 16, 2018
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
Winnie S Liang, Jo-Anne Vergilio, Bodour Salhia, et al.
Journal for Immunotherapy of Cancer
|
August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
Vaia Florou, Charalampos S Floudas, Asaf Maoz, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 181) with videos related to
Sort By:
Page
of 19
British Journal of Cancer
|
May 26, 2023
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
Anthony B El-Khoueiry, James Clarke, Tobias Neff, et al.
Molecular Cancer Therapeutics
|
January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
Filip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.
International Journal of Cancer
|
January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
Ignacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Filip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Cancer Biology & Therapy
|
July 20, 2011
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
Georg Feldmann, Anjali Mishra, Savita Bisht, et al.
Oncotarget
|
December 19, 2012
PIK3CA mutations in advanced cancers: characteristics and outcomes
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
JCO Precision Oncology
|
May 9, 2024
Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets
Erik B Faber, Harris B Krause, Khalid Amin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2011
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer
Ignacio Garrido-Laguna, Maria Uson, N V Rajeshkumar, et al.
The Oncologist
|
August 16, 2018
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
Winnie S Liang, Jo-Anne Vergilio, Bodour Salhia, et al.
Journal for Immunotherapy of Cancer
|
August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
Vaia Florou, Charalampos S Floudas, Asaf Maoz, et al.
Page
of 19